IL1B and chronic granulomatous disease: Clinical improvements of colitis in CGD patients were reported upon IL-1 blockage (18) and upon thalidomide treatment which led to suppression of TNF-α induced NFκB activation, a decreased bowel inflammation characteristic and reduced serum cytokines (19).